Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
Report Scope:
This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report.
Report Includes:
This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report.
Report Includes:
- 31 data tables and 63 additional tables
- An overview of the global market for the technologies for prevention and treatment of prostate cancer
- Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
- Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region
- Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas
- Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations
- Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer
- Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer
- Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios
- Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer
- Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies
- Profiles of leading market participants
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
What's New in this Update?
Methodology and Information Sources
Geographic Breakdown
Segmentation Breakdown
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Market Outlook
Market Summary
CHAPTER 3 MARKET OVERVIEW
Overview of Cancer
Prostate Cancer
Biology of Prostate Cancer
Symptoms
Screening
Diagnosis
Localized Prostate Cancer
Metastatic Prostate Cancer
Watchful Waiting or Active Surveillance
Treatment
Conclusions
CHAPTER 4 MARKET DYNAMICS
Overview
Market Drivers
Increasing Prevalence of Prostate Cancer
Active Surveillance and Screening
Personalized Care
Approvals for Metastatic Castration-Resistant Prostate Cancer
Collaborations and Licensing Agreements
Market Challenges
Loss of Exclusivity and Genericization
Shortage of Care Providers and Other Resources
Market Opportunities
CHAPTER 5 SCREENING AND DIAGNOSIS MARKET BY TEST TYPE
Market Overview
Biomarker Tests
PSA Tests
Limitations of PSA Tests
Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings
Digital Rectal Exam
Limitations of DREs
Prostate Biopsy
Grade (Gleason Score) of Prostate Cancer
Prostatic Intraepithelial Neoplasia
Atypical Small Acinar Proliferation
Proliferative Inflammatory Atrophy
Intraductal Carcinoma of the Prostate
Limitations of Prostate Biopsies
Imaging Technologies for Prostate Cancer
Market for Prostate Cancer Screening/Diagnosis, by Test Type
Biomarker Tests
DREs
Prostate Biopsies
CHAPTER 6 PHARMACEUTICALS MARKET BY DRUG TYPE
Market Overview
Hormone Therapy
Androgen Deprivation Therapy
Antiandrogen Therapies
Hormone Therapy Uses in Prostate Cancer Treatment
Targeted Therapy
PARP Inhibitors
Radioligand Therapies
Small Molecule Targeted Agents
Monoclonal Antibodies
Chemotherapy
Immunotherapy
Market Revenue, by Drug Type
Hormone Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
CHAPTER 7 MARKET FOR SURGERY AND RADIATION THERAPY BY TREATMENT TYPE
Market Overview
Active Surveillance
Radical Prostatectomy
Robotic Prostatectomy
Open Radical Prostatectomy
Laparoscopic Prostatectomy
Radical Prostatectomy Market Revenue
Radiation Therapy
External Beam Radiation Therapy
Brachytherapy
Combined Radiation Therapy
Radiation Therapy Device Market Revenue
CHAPTER 8 MARKET BREAKDOWN BY REGION
Market Overview
Market Revenue, by Region
North America
Market Revenue, by Product Type
Europe
Market Revenue, by Product Type
Asia-Pacific
Market Revenue, by Product Type
Rest of the World (RoW)
Market Revenue, by Product Type
CHAPTER 9 EMERGING TECHNOLOGIES AND DEVELOPMENTS
Overview
Liquid Biopsy
Multiparametric MRI
Homologous Recombination Repair Gene Mutation
Advanced Radiotherapy Techniques
AI and Machine Learning
CHAPTER 10 PIPELINE ANALYSIS
Overview
By Company
CHAPTER 11 COMPETITIVE INTELLIGENCE
Overview
Screening and Diagnosis Market
Market for Radiation Therapy Devices
Pharmaceuticals Market
CHAPTER 12 COMPANY PROFILES
ABBOTT
ACCURAY INC.
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
BAYER AG
DANAHER CORP.
DENDREON PHARMACEUTICALS LLC
ELEKTA
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
PFIZER INC.
SANOFI
SIEMENS HEALTHINEERS AG
CHAPTER 13 APPENDIX: ABBREVIATIONS
Study Goals and Objectives
Reasons for Doing this Study
Scope of Report
What's New in this Update?
Methodology and Information Sources
Geographic Breakdown
Segmentation Breakdown
CHAPTER 2 SUMMARY AND HIGHLIGHTS
Market Outlook
Market Summary
CHAPTER 3 MARKET OVERVIEW
Overview of Cancer
Prostate Cancer
Biology of Prostate Cancer
Symptoms
Screening
Diagnosis
Localized Prostate Cancer
Metastatic Prostate Cancer
Watchful Waiting or Active Surveillance
Treatment
Conclusions
CHAPTER 4 MARKET DYNAMICS
Overview
Market Drivers
Increasing Prevalence of Prostate Cancer
Active Surveillance and Screening
Personalized Care
Approvals for Metastatic Castration-Resistant Prostate Cancer
Collaborations and Licensing Agreements
Market Challenges
Loss of Exclusivity and Genericization
Shortage of Care Providers and Other Resources
Market Opportunities
CHAPTER 5 SCREENING AND DIAGNOSIS MARKET BY TEST TYPE
Market Overview
Biomarker Tests
PSA Tests
Limitations of PSA Tests
Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings
Digital Rectal Exam
Limitations of DREs
Prostate Biopsy
Grade (Gleason Score) of Prostate Cancer
Prostatic Intraepithelial Neoplasia
Atypical Small Acinar Proliferation
Proliferative Inflammatory Atrophy
Intraductal Carcinoma of the Prostate
Limitations of Prostate Biopsies
Imaging Technologies for Prostate Cancer
Market for Prostate Cancer Screening/Diagnosis, by Test Type
Biomarker Tests
DREs
Prostate Biopsies
CHAPTER 6 PHARMACEUTICALS MARKET BY DRUG TYPE
Market Overview
Hormone Therapy
Androgen Deprivation Therapy
Antiandrogen Therapies
Hormone Therapy Uses in Prostate Cancer Treatment
Targeted Therapy
PARP Inhibitors
Radioligand Therapies
Small Molecule Targeted Agents
Monoclonal Antibodies
Chemotherapy
Immunotherapy
Market Revenue, by Drug Type
Hormone Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
CHAPTER 7 MARKET FOR SURGERY AND RADIATION THERAPY BY TREATMENT TYPE
Market Overview
Active Surveillance
Radical Prostatectomy
Robotic Prostatectomy
Open Radical Prostatectomy
Laparoscopic Prostatectomy
Radical Prostatectomy Market Revenue
Radiation Therapy
External Beam Radiation Therapy
Brachytherapy
Combined Radiation Therapy
Radiation Therapy Device Market Revenue
CHAPTER 8 MARKET BREAKDOWN BY REGION
Market Overview
Market Revenue, by Region
North America
Market Revenue, by Product Type
Europe
Market Revenue, by Product Type
Asia-Pacific
Market Revenue, by Product Type
Rest of the World (RoW)
Market Revenue, by Product Type
CHAPTER 9 EMERGING TECHNOLOGIES AND DEVELOPMENTS
Overview
Liquid Biopsy
Multiparametric MRI
Homologous Recombination Repair Gene Mutation
Advanced Radiotherapy Techniques
AI and Machine Learning
CHAPTER 10 PIPELINE ANALYSIS
Overview
By Company
CHAPTER 11 COMPETITIVE INTELLIGENCE
Overview
Screening and Diagnosis Market
Market for Radiation Therapy Devices
Pharmaceuticals Market
CHAPTER 12 COMPANY PROFILES
ABBOTT
ACCURAY INC.
ASTELLAS PHARMA INC.
ASTRAZENECA PLC
BAYER AG
DANAHER CORP.
DENDREON PHARMACEUTICALS LLC
ELEKTA
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
PFIZER INC.
SANOFI
SIEMENS HEALTHINEERS AG
CHAPTER 13 APPENDIX: ABBREVIATIONS
LIST OF TABLES
Summary Table : Global Market for Prostate Cancer Care, by Type, Through 2028
Table 1 : Four Stages of Prostate Cancer
Table 2 : Prostate Cancer: Local and Metastatic Symptoms
Table 3 : Current Prostate Cancer Treatment Options
Table 4 : Prostate Cancer: Major Points
Table 5 : Estimated Number of New Prostate Cancer Cases, by Region, 2020 to 2040
Table 6 : Key Biomarkers for Prostate Cancer
Table 7 : First-Time Generic Drug Approvals for Prostate Cancer, 2021 to November 2023
Table 8 : ACS, NCCN and USPSTF Guidelines on PSA Screening Tests
Table 9 : Additional Biomarker Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings
Table 10 : NCCN and USPSTF Guidelines on Use of DRE for Prostate Cancer Screening
Table 11 : Imaging Technologies for Prostate Cancer
Table 12 : Prostate Cancer Screening and Diagnostic Methods
Table 13 : Global Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 14 : Hormone Therapy Drugs Approved for Prostate Cancer Treatment
Table 15 : PARP Inhibitors Approved for Prostate Cancer Treatment
Table 16 : Radioligand Drugs Approved for Prostate Cancer Treatment
Table 17 : Chemotherapy Drugs Approved for Prostate Cancer Treatment
Table 18 : Immunotherapy Approved for Prostate Cancer Treatment
Table 19 : Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, Through 2028
Table 20 : Global Market for Hormone Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028
Table 21 : Global Market for Targeted Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028
Table 22 : Treatment Options for Prostate Cancer
Table 23 : Advantages and Disadvantages of Radical Prostatectomy
Table 24 : Global Market for Radical Prostatectomy, Through 2028
Table 25 : Comparison of Low- and High-Dose Radiation Therapy
Table 26 : Comparison of EBRT and Brachytherapy
Table 27 : Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, Through 2028
Table 28 : Advances in EBRT
Table 29 : Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region, Through 2028
Table 30 : North American Market for Prostate Cancer Care, by Product Type, Through 2028
Table 31 : North American Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 32 : Europe: Prostate Cancer Incidence, Mortality and Prevalence, 2020
Table 33 : European Market for Prostate Cancer Care, by Product Type, Through 2028
Table 34 : European Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 35 : Worldwide Number of New Prostate Cancer Cases, by Region, 2020, 2030, 2040
Table 36 : Asia-Pacific Market for Prostate Cancer Care, by Product Type, Through 2028
Table 37 : Asia-Pacific Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 38 : RoW Market for Prostate Cancer Care, by Product Type, Through 2028
Table 39 : Liquid Biopsy Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings
Table 40 : PARP Inhibitors in Phase 3 Clinical Trials
Table 41 : Companies with Two or More Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Company, as of November 2023
Table 42 : Prostate Cancer Drugs Pipeline (Phase III Industry Trials)
Table 43 : Ranking of Companies in the Market for Biomarker Tests for Prostate Cancer Screening and Diagnosis, 2022
Table 44 : Ranking of Companies in the Market for Radiation Therapy Devices for Prostate Cancer, 2022
Table 45 : Abbott: Company Snapshot
Table 46 : Abbott: Financial Performance, FY 2021 and 2022
Table 47 : Abbott: Prostate Cancer Product Portfolio
Table 48 : Accuracy Inc.: Company Snapshot
Table 49 : Accuracy Inc.: Financial Performance, FY 2022 and 2023
Table 50 : Accuray Inc.: Radiotherapy Product Portfolio
Table 51 : Accuray Inc.: Recent Developments, 2022-2023
Table 52 : Astellas Pharma Inc.: Company Snapshot
Table 53 : Astellas Pharma Inc.: Financial Performance, FY 2021 and 2022
Table 54 : Astellas Pharma Inc.: Prostate Cancer Drug Portfolio
Table 55 : Astellas Pharma Inc.: Recent Developments, 2021-2023
Table 56 : AstraZeneca Plc: Company Snapshot
Table 57 : AstraZeneca Plc: Financial Performance, FY 2021 and 2022
Table 58 : AstraZeneca Plc: Prostate Cancer Drug Portfolio
Table 59 : AstraZeneca Plc: Recent Developments, 2022-2023
Table 60 : Bayer AG: Company Snapshot
Table 61 : Bayer AG: Financial Performance, FY 2021 and 2022
Table 62 : Bayer AG: Prostate Cancer Drugs Portfolio
Table 63 : Bayer AG: Recent Developments, 2021-2023
Table 64 : Danaher Corp.: Company Snapshot
Table 65 : Danaher Corp.: Financial Performance, FY 2021 and 2022
Table 66 : Danaher Corp.: Prostate Health Product Portfolio
Table 67 : Dendreon Pharmaceuticals LLC: Company Snapshot
Table 68 : Dendreon Pharmaceuticals LLC: Prostate Cancer Drug Portfolio
Table 69 : Elekta: Company Snapshot
Table 70 : Elekta: Financial Performance, FY 2022 and 2023
Table 71 : Elekta: Radiotherapy Product Portfolio
Table 72 : Elekta: Recent Developments, 2021-2023
Table 73 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 74 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2021 and 2022
Table 75 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 76 : F. Hoffmann-La Roche Ltd.: Recent Developments, 2023
Table 77 : Johnson & Johnson Services, Inc.: Company Snapshot
Table 78 : Johnson & Johnson Services, Inc.: Financial Performance, FY 2021 and 2022
Table 79 : Johnson & Johnson Services, Inc.: Prostate Cancer Drug Portfolio
Table 80 : Johnson & Johnson Services, Inc.: Recent Developments, 2023
Table 81 : Pfizer Inc.: Company Snapshot
Table 82 : Pfizer Inc.: Financial Performance, FY 2021 and 2022
Table 83 : Pfizer Inc.: Prostate Cancer Drugs Portfolio
Table 84 : Pfizer Inc.: Recent Developments, 2022-2023
Table 85 : Sanofi: Company Snapshot
Table 86 : Sanofi: Financial Performance, FY 2021 and 2022
Table 87 : Sanofi: Prostate Cancer Drug Portfolio
Table 88 : Sanofi: Recent Developments, 2022
Table 89 : Siemens Healthineers: Company Snapshot
Table 90 : Siemens Healthineers: Financial Performance, FY 2022 and 2023
Table 91 : Siemens Healthineers: Prostate Cancer Product Portfolio
Table 92 : Siemens Healthineers: Recent Developments, 2022-2023
Table 93 : Abbreviations Used in this Report
Summary Table : Global Market for Prostate Cancer Care, by Type, Through 2028
Table 1 : Four Stages of Prostate Cancer
Table 2 : Prostate Cancer: Local and Metastatic Symptoms
Table 3 : Current Prostate Cancer Treatment Options
Table 4 : Prostate Cancer: Major Points
Table 5 : Estimated Number of New Prostate Cancer Cases, by Region, 2020 to 2040
Table 6 : Key Biomarkers for Prostate Cancer
Table 7 : First-Time Generic Drug Approvals for Prostate Cancer, 2021 to November 2023
Table 8 : ACS, NCCN and USPSTF Guidelines on PSA Screening Tests
Table 9 : Additional Biomarker Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings
Table 10 : NCCN and USPSTF Guidelines on Use of DRE for Prostate Cancer Screening
Table 11 : Imaging Technologies for Prostate Cancer
Table 12 : Prostate Cancer Screening and Diagnostic Methods
Table 13 : Global Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 14 : Hormone Therapy Drugs Approved for Prostate Cancer Treatment
Table 15 : PARP Inhibitors Approved for Prostate Cancer Treatment
Table 16 : Radioligand Drugs Approved for Prostate Cancer Treatment
Table 17 : Chemotherapy Drugs Approved for Prostate Cancer Treatment
Table 18 : Immunotherapy Approved for Prostate Cancer Treatment
Table 19 : Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, Through 2028
Table 20 : Global Market for Hormone Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028
Table 21 : Global Market for Targeted Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028
Table 22 : Treatment Options for Prostate Cancer
Table 23 : Advantages and Disadvantages of Radical Prostatectomy
Table 24 : Global Market for Radical Prostatectomy, Through 2028
Table 25 : Comparison of Low- and High-Dose Radiation Therapy
Table 26 : Comparison of EBRT and Brachytherapy
Table 27 : Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, Through 2028
Table 28 : Advances in EBRT
Table 29 : Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region, Through 2028
Table 30 : North American Market for Prostate Cancer Care, by Product Type, Through 2028
Table 31 : North American Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 32 : Europe: Prostate Cancer Incidence, Mortality and Prevalence, 2020
Table 33 : European Market for Prostate Cancer Care, by Product Type, Through 2028
Table 34 : European Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 35 : Worldwide Number of New Prostate Cancer Cases, by Region, 2020, 2030, 2040
Table 36 : Asia-Pacific Market for Prostate Cancer Care, by Product Type, Through 2028
Table 37 : Asia-Pacific Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
Table 38 : RoW Market for Prostate Cancer Care, by Product Type, Through 2028
Table 39 : Liquid Biopsy Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings
Table 40 : PARP Inhibitors in Phase 3 Clinical Trials
Table 41 : Companies with Two or More Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Company, as of November 2023
Table 42 : Prostate Cancer Drugs Pipeline (Phase III Industry Trials)
Table 43 : Ranking of Companies in the Market for Biomarker Tests for Prostate Cancer Screening and Diagnosis, 2022
Table 44 : Ranking of Companies in the Market for Radiation Therapy Devices for Prostate Cancer, 2022
Table 45 : Abbott: Company Snapshot
Table 46 : Abbott: Financial Performance, FY 2021 and 2022
Table 47 : Abbott: Prostate Cancer Product Portfolio
Table 48 : Accuracy Inc.: Company Snapshot
Table 49 : Accuracy Inc.: Financial Performance, FY 2022 and 2023
Table 50 : Accuray Inc.: Radiotherapy Product Portfolio
Table 51 : Accuray Inc.: Recent Developments, 2022-2023
Table 52 : Astellas Pharma Inc.: Company Snapshot
Table 53 : Astellas Pharma Inc.: Financial Performance, FY 2021 and 2022
Table 54 : Astellas Pharma Inc.: Prostate Cancer Drug Portfolio
Table 55 : Astellas Pharma Inc.: Recent Developments, 2021-2023
Table 56 : AstraZeneca Plc: Company Snapshot
Table 57 : AstraZeneca Plc: Financial Performance, FY 2021 and 2022
Table 58 : AstraZeneca Plc: Prostate Cancer Drug Portfolio
Table 59 : AstraZeneca Plc: Recent Developments, 2022-2023
Table 60 : Bayer AG: Company Snapshot
Table 61 : Bayer AG: Financial Performance, FY 2021 and 2022
Table 62 : Bayer AG: Prostate Cancer Drugs Portfolio
Table 63 : Bayer AG: Recent Developments, 2021-2023
Table 64 : Danaher Corp.: Company Snapshot
Table 65 : Danaher Corp.: Financial Performance, FY 2021 and 2022
Table 66 : Danaher Corp.: Prostate Health Product Portfolio
Table 67 : Dendreon Pharmaceuticals LLC: Company Snapshot
Table 68 : Dendreon Pharmaceuticals LLC: Prostate Cancer Drug Portfolio
Table 69 : Elekta: Company Snapshot
Table 70 : Elekta: Financial Performance, FY 2022 and 2023
Table 71 : Elekta: Radiotherapy Product Portfolio
Table 72 : Elekta: Recent Developments, 2021-2023
Table 73 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 74 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2021 and 2022
Table 75 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 76 : F. Hoffmann-La Roche Ltd.: Recent Developments, 2023
Table 77 : Johnson & Johnson Services, Inc.: Company Snapshot
Table 78 : Johnson & Johnson Services, Inc.: Financial Performance, FY 2021 and 2022
Table 79 : Johnson & Johnson Services, Inc.: Prostate Cancer Drug Portfolio
Table 80 : Johnson & Johnson Services, Inc.: Recent Developments, 2023
Table 81 : Pfizer Inc.: Company Snapshot
Table 82 : Pfizer Inc.: Financial Performance, FY 2021 and 2022
Table 83 : Pfizer Inc.: Prostate Cancer Drugs Portfolio
Table 84 : Pfizer Inc.: Recent Developments, 2022-2023
Table 85 : Sanofi: Company Snapshot
Table 86 : Sanofi: Financial Performance, FY 2021 and 2022
Table 87 : Sanofi: Prostate Cancer Drug Portfolio
Table 88 : Sanofi: Recent Developments, 2022
Table 89 : Siemens Healthineers: Company Snapshot
Table 90 : Siemens Healthineers: Financial Performance, FY 2022 and 2023
Table 91 : Siemens Healthineers: Prostate Cancer Product Portfolio
Table 92 : Siemens Healthineers: Recent Developments, 2022-2023
Table 93 : Abbreviations Used in this Report
LIST OF FIGURES
Summary Figure A : Global Market for Prostate Cancer Care, by Type, 2020-2028
Summary Figure B : Global Market Shares of Prostate Cancer Care, by Type, 2022
Figure 1 : Cancer Care Spectrum
Figure 2 : Prostate Cancer Risk Group
Figure 3 : Prostate Cancer Advancements
Figure 4 : Prostate Cancer Care Market Dynamics
Figure 5 : Estimated Number of New Prostate Cancer Cases, by Region, 2020 and 2040
Figure 6 : Share of Prostate Cancer Cases, by Stage
Figure 7 : Prostate Cancer Incidence in the U.S.
Figure 8 : Cancer Radiotherapy Systems Treatment, by Region, 2021
Figure 9 : Prostate Cancer 5-Year Relative Survival Rates
Figure 10 : Trends in Oncology
Figure 11 : Global Market for Prostate Cancer Screening and Detection, by Test Type, 2020-2028
Figure 12 : Global Market Shares of Prostate Cancer Screening and Detection, by Test Type, 2022
Figure 13 : Benefits of Immunotherapy
Figure 14 : Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, 2020-2028
Figure 15 : Global Market Shares of Prostate Cancer Pharmaceuticals, by Drug Type, 2022
Figure 16 : Global Market Shares of Hormone Therapy Drugs for Prostate Cancer, by Drug Type, 2022
Figure 17 : Global Market Shares of Targeted Therapy Drugs for Prostate Cancer, by Drug Type, 2022
Figure 18 : Global Market for Radical Prostatectomy, 2020-2028
Figure 19 : Types of Radiation
Figure 20 : Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2020-2028
Figure 21 : Global Market Shares of Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2022
Figure 22 : Snapshot of Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region
Figure 23 : Global Market Shares of Prostate Cancer Screening, Diagnosis and Treatment, by Region, 2022
Figure 24 : Estimated Number of Prostate Cancer Cases in the U.S., Both Sexes, 2020 to 2040
Figure 25 : North American Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 26 : European Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 27 : Worldwide Distribution of New Prostate Cancer Cases, by Region, 2020-2040
Figure 28 : Asia-Pacific Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 29 : RoW Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 30 : Emerging Technologies in Prostate Cancer Care
Figure 31 : Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Cancer Type, as of November 2023
Figure 32 : Share of Active Clinical Trials in Phase 2 or 3 for Castration-Resistant Prostate Cancer (CRPC), by Cancer Type, as of November 2023
Figure 33 : Global Market Share of Prostate Cancer Pharmaceutical, by Company, 2022
Figure 34 : Abbott: Revenue Share, by Business Unit, FY 2022
Figure 35 : Abbott: Revenue Share, by Region, FY 2022
Figure 36 : Accuray Inc.: Revenue Share, by Product Type, FY 2023
Figure 37 : Accuray Inc.: Revenue Share, by Region, FY 2023
Figure 38 : Astellas Pharma Inc.: Revenue Share, by Product, 2022
Figure 39 : Astellas Pharma Inc.: Revenue Share, by Region, 2022
Figure 40 : AstraZeneca Plc: Revenue Share, by Therapy Area, 2022
Figure 41 : AstraZeneca Plc: Revenue Share, by Region, 2022
Figure 42 : Bayer AG: Revenue Share, by Business Segment, 2022
Figure 43 : Bayer AG: Revenue Share, by Region, 2022
Figure 44 : Danaher Corp.: Market Share, by Business Segment, 2022
Figure 45 : Danaher Corp.: Revenue Share, by Region, 2022
Figure 46 : Elekta: Revenue Share, by Product Type, 2023
Figure 47 : Elekta: Revenue Share, by Region, 2023
Figure 48 : F. Hoffmann-La Roche Ltd.: Market Share, by Business Segment, 2022
Figure 49 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2022
Figure 50 : Johnson & Johnson Services, Inc.: Revenue Share, by Business Segment, 2022
Figure 51 : Johnson & Johnson Services, Inc.: Revenue Share, by Region, 2022
Figure 52 : Pfizer Inc.: Revenue Share, by Business Unit, 2022
Figure 53 : Pfizer Inc.: Revenue Share, by Region, 2022
Figure 54 : Sanofi: Revenue Share, by Global Business Unit, 2022
Figure 55 : Sanofi: Revenue Share, by Region, 2022
Figure 56 : Siemens Healthineers: Revenue Share, by Segment, 2023
Figure 57 : Siemens Healthineers: Revenue Share, by Region, 2023
Summary Figure A : Global Market for Prostate Cancer Care, by Type, 2020-2028
Summary Figure B : Global Market Shares of Prostate Cancer Care, by Type, 2022
Figure 1 : Cancer Care Spectrum
Figure 2 : Prostate Cancer Risk Group
Figure 3 : Prostate Cancer Advancements
Figure 4 : Prostate Cancer Care Market Dynamics
Figure 5 : Estimated Number of New Prostate Cancer Cases, by Region, 2020 and 2040
Figure 6 : Share of Prostate Cancer Cases, by Stage
Figure 7 : Prostate Cancer Incidence in the U.S.
Figure 8 : Cancer Radiotherapy Systems Treatment, by Region, 2021
Figure 9 : Prostate Cancer 5-Year Relative Survival Rates
Figure 10 : Trends in Oncology
Figure 11 : Global Market for Prostate Cancer Screening and Detection, by Test Type, 2020-2028
Figure 12 : Global Market Shares of Prostate Cancer Screening and Detection, by Test Type, 2022
Figure 13 : Benefits of Immunotherapy
Figure 14 : Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, 2020-2028
Figure 15 : Global Market Shares of Prostate Cancer Pharmaceuticals, by Drug Type, 2022
Figure 16 : Global Market Shares of Hormone Therapy Drugs for Prostate Cancer, by Drug Type, 2022
Figure 17 : Global Market Shares of Targeted Therapy Drugs for Prostate Cancer, by Drug Type, 2022
Figure 18 : Global Market for Radical Prostatectomy, 2020-2028
Figure 19 : Types of Radiation
Figure 20 : Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2020-2028
Figure 21 : Global Market Shares of Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2022
Figure 22 : Snapshot of Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region
Figure 23 : Global Market Shares of Prostate Cancer Screening, Diagnosis and Treatment, by Region, 2022
Figure 24 : Estimated Number of Prostate Cancer Cases in the U.S., Both Sexes, 2020 to 2040
Figure 25 : North American Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 26 : European Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 27 : Worldwide Distribution of New Prostate Cancer Cases, by Region, 2020-2040
Figure 28 : Asia-Pacific Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 29 : RoW Market for Prostate Cancer Care, by Product Type, 2020-2028
Figure 30 : Emerging Technologies in Prostate Cancer Care
Figure 31 : Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Cancer Type, as of November 2023
Figure 32 : Share of Active Clinical Trials in Phase 2 or 3 for Castration-Resistant Prostate Cancer (CRPC), by Cancer Type, as of November 2023
Figure 33 : Global Market Share of Prostate Cancer Pharmaceutical, by Company, 2022
Figure 34 : Abbott: Revenue Share, by Business Unit, FY 2022
Figure 35 : Abbott: Revenue Share, by Region, FY 2022
Figure 36 : Accuray Inc.: Revenue Share, by Product Type, FY 2023
Figure 37 : Accuray Inc.: Revenue Share, by Region, FY 2023
Figure 38 : Astellas Pharma Inc.: Revenue Share, by Product, 2022
Figure 39 : Astellas Pharma Inc.: Revenue Share, by Region, 2022
Figure 40 : AstraZeneca Plc: Revenue Share, by Therapy Area, 2022
Figure 41 : AstraZeneca Plc: Revenue Share, by Region, 2022
Figure 42 : Bayer AG: Revenue Share, by Business Segment, 2022
Figure 43 : Bayer AG: Revenue Share, by Region, 2022
Figure 44 : Danaher Corp.: Market Share, by Business Segment, 2022
Figure 45 : Danaher Corp.: Revenue Share, by Region, 2022
Figure 46 : Elekta: Revenue Share, by Product Type, 2023
Figure 47 : Elekta: Revenue Share, by Region, 2023
Figure 48 : F. Hoffmann-La Roche Ltd.: Market Share, by Business Segment, 2022
Figure 49 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2022
Figure 50 : Johnson & Johnson Services, Inc.: Revenue Share, by Business Segment, 2022
Figure 51 : Johnson & Johnson Services, Inc.: Revenue Share, by Region, 2022
Figure 52 : Pfizer Inc.: Revenue Share, by Business Unit, 2022
Figure 53 : Pfizer Inc.: Revenue Share, by Region, 2022
Figure 54 : Sanofi: Revenue Share, by Global Business Unit, 2022
Figure 55 : Sanofi: Revenue Share, by Region, 2022
Figure 56 : Siemens Healthineers: Revenue Share, by Segment, 2023
Figure 57 : Siemens Healthineers: Revenue Share, by Region, 2023
